Abstract | BACKGROUND: Treatment of type 2 diabetes mellitus invariably requires the use of multiple daily medications which can impact negatively on patient adherence. As a result, there is growing interest in the use of single-pill combinations that can reduce the pill burden. Many such formulations incorporate metformin, although this agent is not suitable for all patients. The single-pill combination of the dipeptidyl peptidase-4 inhibitor linagliptin with the sodium glucose co-transporter 2 inhibitor empagliflozin offers a new and attractive option, given their complementary mechanisms of action. SCOPE: Publications with titles containing the keywords ' linagliptin' or ' empagliflozin' were identified from a non-systematic search of PubMed without date restrictions, together with abstracts presented at the annual meetings of the American Diabetes Association and the European Association for the Study of Diabetes 2012-2014. ClinicalTrials.gov was searched for entries containing these two keywords. Additional references known to the author were included. FINDINGS: CONCLUSIONS: The single-pill combination of linagliptin and empagliflozin, with their complementary mechanisms of action, is a promising treatment option for patients with type 2 diabetes mellitus. It would reduce the daily pill burden in this population, potentially improving adherence to, and optimizing the benefits of, treatment of diabetes mellitus.
|
Authors | Ronnie Aronson |
Journal | Current medical research and opinion
(Curr Med Res Opin)
Vol. 31
Issue 5
Pg. 901-11
(May 2015)
ISSN: 1473-4877 [Electronic] England |
PMID | 25775379
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Benzhydryl Compounds
- Blood Glucose
- Dipeptidyl-Peptidase IV Inhibitors
- Drug Combinations
- Glucosides
- Hypoglycemic Agents
- Purines
- Quinazolines
- Linagliptin
- empagliflozin
|
Topics |
- Benzhydryl Compounds
(administration & dosage, therapeutic use)
- Blood Glucose
(drug effects)
- Diabetes Mellitus, Type 2
(drug therapy)
- Dipeptidyl-Peptidase IV Inhibitors
(administration & dosage, therapeutic use)
- Drug Combinations
- Glucosides
(administration & dosage, therapeutic use)
- Humans
- Hypoglycemic Agents
(administration & dosage, therapeutic use)
- Linagliptin
- Purines
(administration & dosage, therapeutic use)
- Quinazolines
(administration & dosage, therapeutic use)
|